Table 1.
Demographic and clinical data.
| Demographic data | Mean (%) |
|---|---|
| Age, yrs | 67 ± 16.48 |
| Sex (F) | 25 (36.8) |
| Clinical data | |
| Smokers | 3 (4.4) |
| Ex-smokers | 18 (26.5) |
| Vax-Complete cycle | 30 (44.1) |
| Vax-Incomplete cycle | 6 (8.8) |
| Hypertension | 34 (50.0) |
| CV pathology | 29 (42.6) |
| Asthma | 8 (11.8) |
| COPD | 11 (16.2) |
| Ictus | 4 (5.9) |
| Cerebrovascular pathology | 11 (16.2) |
| Dementia | 2 (2.9) |
| Obesity | 12 (17.2) |
| Dyslipidaemia | 15 (22.1) |
| Solid cancer | 12 (17.2) |
| Haematologic cancer | 10 (14.7) |
| Symptoms | |
| Fever | 41 (60.3) |
| Dyspnoea | 36 (52.9) |
| Cough | 25 (36.8) |
| Therapy | |
| O2in emergency room | 50 (73.5) |
| O2at Hospital | 59 (86.8) |
| NIV therapy (BPAP or CPAP) | 15 (22.1) |
| CN high flux | 15 (22.1) |
| Corticosteroids | 62 (91.2) |
| Antithrombotics | 53 (77.9) |
| Antiviral | 25 (36.8) |
| Outcome | |
| IUC/Sub-IUC | 18 (26.5) |
| Respiratory failure | 52 (76.5) |
| Facility discharge | 15 (22.1) |
| Respiratory supports at the discharge time | 10 (14.7) |
| Bacterial over-infection | 25 (36.8) |
| Thrombotic complications | 5 (7.4) |
Abbreviations: F:female;COPD:Chronic obstructive pulmonary disease;CV pathology:cardio-vascular pathology;NIV: non-invasive ventilation;BPAP:bilevel positive airway pressure;CPAP:Continuous Positive airway Pressure;CN:nasal canula;Corticosteroids used: dexamethasone, hydrocortisone, methylprednisone. The most used was dexamethasone; Antithrombotic therapy: New oral anticoagulants (NAO), Clexane, Coumadin, Arixtra; IUC/Sub-IUC, intensive unit care/sub-intensive unit care; The most used was Clexane. Data are presented as mean ± S.D or number (%, percentage).